Advancing access to myeloma treatment: administration, side effects, and implications for survival.

Davies, Marianne J

Davies, Marianne J.

Affiliation

Davies MJ; Yale University School of Medicine, Section of Medical Oncology, Yale Cancer Center, New Haven, CT, USA.

ONS News ; 21(8 Suppl): 11-2, 2006.

Article in En | MEDLINE | ID: mdl-16925131

Subject(s)

Multiple Myeloma/therapy; Oncology Nursing/organization & administration; Antineoplastic Agents/therapeutic use; Boronic Acids/therapeutic use; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibility; Humans; Immunosuppressive Agents/therapeutic use; Information Services; Lenalidomide; Multiple Myeloma/etiology; Multiple Myeloma/mortality; Nurse's Role; Patient Education as Topic; Protease Inhibitors/therapeutic use; Pyrazines/therapeutic use; Radiotherapy, Adjuvant; Stem Cell Transplantation/methods; Stem Cell Transplantation/nursing; Survival Rate; Thalidomide/analogs & derivatives; Thalidomide/therapeutic use

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Oncology Nursing / Multiple Myeloma Type of study: Etiology_studies Limits: Humans Language: En Year: 2006 Type: Article

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Oncology Nursing / Multiple Myeloma Type of study: Etiology_studies Limits: Humans Language: En Year: 2006 Type: Article